Skip to content

The role of EMDR in the reduction of psychological symptoms in patients with personality disorders.

The role of EMDR in the reduction of psychological symptoms in patients with personality disorders. - EMDR in personality disorders.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45418
Enrollment
52
Registered
2017-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality disorder

Interventions

Eye Movement Desensitization and Reprocessing is a therapy for people who as a result of traumatic events experience psychological symptoms.It has already proven to be effective in the treatment of
EMDR
Personality disorders
Trauma

Sponsors

GGZ Delfland (Delft)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients are included if they are diagnosed with a personality disorder, are between 18 and 75 years old and provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients suffering from Post Traumatic Stress Disorder (PTSD) or an addiction diagnosed during intake are excluded from the study.

Design outcomes

Primary

MeasureTime frame
BSI: The Brief Symptom Inventory (BSI; De Beurs & Zitman, 2006) is a 53-item self-report questionnaire on which participants rate the extent to which they have been bothered by various symptoms in the past week ranging from 0 ("not at all") to 4 ("extremely"). The BSI has nine subscales designed to assess individual symptom groups: somatization (SOM, e.g., "Faintness or dizziness"), obsessive-compulsive behavior (OC, e.g., "Having to check and double-check what you do"), interpersonal sensitivity (IS, e.g., "Feeling inferior to others"), depression (DEP, e.g., "Feeling no interest in things"), anxiety (ANX, e.g., "Feeling tense or keyed up"), hostility (HOS, e.g., "Having urges to break or smash things"), phobic anxiety (PHB, e.g., "Feeling uneasy in crowds, such as shopping or at a movie"), paranoid ideation (PAR, e.g., "Others not giving you proper credit for your achievements"), and psychoticism (PSY, e.g., "The idea that something is wrong with your mind"). The BSI also includes three scales that measure global psychological distress. The BSI is a reliable and validated test and has a good internal consistency: Cronbach*s * is 0,96 (de Beurs, 2008).

Secondary

MeasureTime frame
Schok Verwerkingslijst (Impact of Event Scale) The Schok Verwerkingslijst (SVL) is the Dutch version of the Impact of Event Scale (IES) van Horowitz, Wilner and Alvarez from 1979. It is a 15-item self-report measure that assesses subjective distress caused by traumatic events. Participants rate on a 5 point Likert-scale (0 ="not at all" to 4="extremely") the extent to which they have been bothered in the past week by various symptoms. This questionnaire inventarizes two characteristic PTSD dimensions: re-experiencing the traumatic event and avoidance of feelings and memories about the traumatic event. The reliability and the validity of the test is good (Ploeg, van der, Mooren, Kleber, Velden, van der & Brom, 2004). The SVL gives a good presentation of the level of intrusions and the level of avoidance after shocking experiences. Internal consistency ranges from * 0.87 to 0.96 for the total score. AAQ-II The Acceptance and Action Questionnaire ( AAQ-II; Bond e.a. 2011) is a 7-item self-report questionnaire and measures experiential avoidance and psychological inflexibility. The items on the AAQ-2 are rated on a 7 point Likert- scale, ranging from 1 (never true) to 7 (always true). High scores on the AAQ-2 reflect greater experiential avoidance and immobility, while low scores reflect greater acceptance and commited action. The psychometric qualities of the Dutch version of the AAQ-II are good with an internal consistency of Cronbach*s * 0.87 (Bernaerts e.a. 2014; Fledderus e.a. 2012; Jacobs e.a. 2008).

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)